# Vector BioMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vector-biomed

- Industry: Pharmaceuticals
- Headquarters: Gaithersburg, US
- Website: www.vectorbiomed.com
- Total disclosed funding: $23M
- Latest round: Series A (Jan 31, 2023)
- Investors on record: 2

## About

Based in Maryland, US, Vector BioMed Inc. provides platform that help its partner in clinical studies and commercialize their lentiviral vector – based medicines. As of 2023 the company is headed by its CEO Boro Dropulic. In January 2023, the firm raised an of Series A funding led by investor Viking Global Investors, with participation from another investor Casdin Capital.

The company offers its partners with rapid access to high – titer lentiviral vectors who require to move quickly to clinical trials, and commercialization. Additionally, the firm platform produce high-titer (>10? TU/ML) Lentiviral vectors which can be used in clinical application and commercialization.

The company plan to use the January 2023 funding to further the development of its studies and product commercialization.

## Funding rounds

- Series A, Jan 31, 2023, $15M — Viking Global Investors, Casdin Capital
- Series A, Nov 30, 2022, $7.5M — Viking Global Investors, Casdin Capital

## Investors

- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A